HARROW, INC.
HARROW, INC. (IMMY): 17 pipeline candidates · ~45 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
44.8 months
D/E 13.63 · 0% dilution
Lead: Approved
17 candidates
N/A
4 buys · 6 sells (180d)
A transparent, data-derived signal for HARROW, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$94.6M
Quarterly Burn
$9.0M
Runway
44.8 mo
Revenue
$44.2M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (17 candidates)
| Drug | Phase |
|---|---|
| byqlovi | Approved |
| chloroprocaine ophthalmic gel 3% | Phase 4 |
| cr-01 | Preclinical |
| fluorometholone acetate ophthalmic suspension 0.1% | Phase 4 |
| h-n08 | Preclinical |
| iheezo | Approved |
| ilevro | Approved |
| loteprednol etabonate ophthalmic gel 0.38% | Phase 4 |
| melt-210 | Phase 2 |
| melt-300 | Phase 3 |
Showing 10 of 17 candidates. Sign up for full pipeline.
Frequently asked questions
How many drug candidates are in HARROW, INC.'s pipeline?
HARROW, INC. (IMMY) has 17 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is HARROW, INC.'s lead drug candidate?
HARROW, INC.'s most advanced tracked candidate is byqlovi (Approved) for 1 INDICATIONS AND USAGE BYQLOVI is indicated for the treatment of post-operative inflammation and pain following ocular surgery. BYQLOVI is a corticosteroid indicated for the treatment of post- operative inflammation and pain following ocular surgery. ( 1 ).
What is HARROW, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, HARROW, INC. has approximately 44.8 months of cash runway.
Who is the CEO of HARROW, INC.?
Mark L. Baum is the chief executive officer of HARROW, INC. (IMMY).
Get the full picture on HARROW, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.